Skip to main content
Fig. 5 | Cancer Nanotechnology

Fig. 5

From: CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo

Fig. 5

Biodistribution of PLD and A6-PLD at different time points (24 and 48 h) in organs including A serum, B liver, spleen, heart, kidney, and lung and C tumor in BALB/c mice bearing C26 tumor after a single dose of 15 mg/kg liposomal doxorubicin administered i.v. 2 weeks after the tumor inoculation. D represents a ratio of doxorubicin concentration in the liver, spleen, heart, and tumor to serum, at 48 h. Data expressed as mean ± SEM. (n = 3)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us